Visceral Fat and Diabetes: Associations With Liver Fibrosis in Metabolic Dysfunction–Associated Steatotic Liver Disease

Abstract

BackgroundThe prevalence of metabolic dysfunction–associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease (NAFLD), is increasing globally. Noninvasive methods, such as bioelectrical impedance analysis (BIA), which measures body composition, including visceral fat, are gaining interest in evaluating MASLD patients. Our study aimed to identify factors associated with significant liver fibrosis, compare noninvasive scores, and highlight the importance of visceral fat measurement using BIA. MethodsMASLD patients seen in our OPD underwent comprehensive evaluations, including liver stiffness using transient elastography, body composition analysis using BIA, and metabolic measurements. Significant fibrosis was defined as liver stiffness measurement ≥8.2 kPa. Using multivariate analysis, we identified factors associated with significant liver fibrosis and compared four noninvasive scores with a novel DVF15 score. ResultsWe analyzed data from 609 MASLD patients seen between February 2022 and March 2023. The median age was 43 years (81% male). Among these, 78 (13%) had significant fibrosis. Patients with significant fibrosis had higher rates of type 2 diabetes (41% vs 21%, p<0.001) and elevated levels of AST, ALT, HbA1c, Fib-4, APRI, and NFS scores. They also exhibited higher visceral and subcutaneous fat. Binary logistic regression revealed type 2 diabetes and visceral fat >15% as associated with significant liver fibrosis. Additionally, the DVF15 score, combining these factors, showed a modest area under the ROC curve of 0.664 (p<0.001). ConclusionOur study identified diabetes and high visceral fat as factors associated with significant liver fibrosis in MASLD patients. We recommend that visceral fat measurement using BIA be an essential part of MASLD evaluation. The presence of either diabetes or visceral fat >15% should prompt clinicians to check for significant fibrosis in MASLD patients. Further research is warranted to validate our findings and evaluate the utility of the DVF15 score in larger cohorts and diverse populations.